Literature DB >> 25492869

Phosphorylation of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) by Akt promotes stability and mitogenic function of S-phase kinase-associated protein-2 (Skp2).

Gyun Jee Song1, Kristen L Leslie2, Stacey Barrick2, Tatyana Mamonova2, Jeremy M Fitzpatrick3, Kenneth W Drombosky2, Noah Peyser2, Bin Wang2, Maria Pellegrini3, Philip M Bauer4, Peter A Friedman2, Dale F Mierke3, Alessandro Bisello5.   

Abstract

The regulation of the cell cycle by the ubiquitin-proteasome system is dependent on the activity of E3 ligases. Skp2 (S-phase kinase associated protein-2) is the substrate recognition subunit of the E3 ligase that ubiquitylates the cell cycle inhibitors p21(cip1) and p27(kip1) thus promoting cell cycle progression. Increased expression of Skp2 is frequently observed in diseases characterized by excessive cell proliferation, such as cancer and neointima hyperplasia. The stability and cellular localization of Skp2 are regulated by Akt, but the molecular mechanisms underlying these effects remain only partly understood. The scaffolding protein Ezrin-Binding Phosphoprotein of 50 kDa (EBP50) contains two PDZ domains and plays a critical role in the development of neointimal hyperplasia. Here we report that EBP50 directly binds Skp2 via its first PDZ domain. Moreover, EBP50 is phosphorylated by Akt on Thr-156 within the second PDZ domain, an event that allosterically promotes binding to Skp2. The interaction with EBP50 causes cytoplasmic localization of Skp2, increases Skp2 stability and promotes proliferation of primary vascular smooth muscle cells. Collectively, these studies define a novel regulatory mechanism contributing to aberrant cell growth and highlight the importance of scaffolding function of EBP50 in Akt-dependent cell proliferation.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Akt PKB; Cell Proliferation; EBP50; PDZ Domain; Phosphorylation; Skp2; Vascular Smooth Muscle Cells; nherf; nherf1

Mesh:

Substances:

Year:  2014        PMID: 25492869      PMCID: PMC4317011          DOI: 10.1074/jbc.M114.609768

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Nuclear localization of the cell cycle regulator CDH1 and its regulation by phosphorylation.

Authors:  Yuan Zhou; Yick-Pang Ching; Abel C S Chun; Dong-Yan Jin
Journal:  J Biol Chem       Date:  2003-01-29       Impact factor: 5.157

2.  p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells.

Authors:  H Sutterlüty; E Chatelain; A Marti; C Wirbelauer; M Senften; U Müller; W Krek
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

3.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

4.  Skp2 is oncogenic and overexpressed in human cancers.

Authors:  M Gstaiger; R Jordan; M Lim; C Catzavelos; J Mestan; J Slingerland; W Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

5.  Role of the F-box protein Skp2 in lymphomagenesis.

Authors:  E Latres; R Chiarle; B A Schulman; N P Pavletich; A Pellicer; G Inghirami; M Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

6.  Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase.

Authors:  Gil Bornstein; Joanna Bloom; Danielle Sitry-Shevah; Keiko Nakayama; Michele Pagano; Avram Hershko
Journal:  J Biol Chem       Date:  2003-05-02       Impact factor: 5.157

7.  Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma.

Authors:  Kazushi Shigemasa; Lijun Gu; Timothy J O'Brien; Koso Ohama
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

8.  Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.

Authors:  Sabina Signoretti; Lucia Di Marcotullio; Andrea Richardson; Sridhar Ramaswamy; Beth Isaac; Montserrat Rue; Franco Monti; Massimo Loda; Michele Pagano
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

9.  Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex.

Authors:  Wenyi Wei; Nagi G Ayad; Yong Wan; Guo-Jun Zhang; Marc W Kirschner; William G Kaelin
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

10.  Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker.

Authors:  Chang Qi Zhu; Fiona H Blackhall; Melania Pintilie; Pratibha Iyengar; Ni Liu; James Ho; Taylor Chomiak; Davina Lau; Timothy Winton; Frances A Shepherd; Ming-Sound Tsao
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

View more
  9 in total

Review 1.  Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance.

Authors:  J Vaquero; T H Nguyen Ho-Bouldoires; A Clapéron; L Fouassier
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

2.  Parathyroid hormone initiates dynamic NHERF1 phosphorylation cycling and conformational changes that regulate NPT2A-dependent phosphate transport.

Authors:  Qiangmin Zhang; Kunhong Xiao; José M Paredes; Tatyana Mamonova; W Bruce Sneddon; Hongda Liu; Dawei Wang; Sheng Li; Jennifer C McGarvey; David Uehling; Rima Al-Awar; Babu Joseph; Frederic Jean-Alphonse; Angel Orte; Peter A Friedman
Journal:  J Biol Chem       Date:  2019-01-29       Impact factor: 5.157

3.  A novel thyroid hormone receptor isoform, TRβ2-46, promotes SKP2 expression and retinoblastoma cell proliferation.

Authors:  Zhengke Li; Dong-Lai Qi; Hardeep P Singh; Yue Zou; Binghui Shen; David Cobrinik
Journal:  J Biol Chem       Date:  2019-01-14       Impact factor: 5.157

4.  Adenosine Attenuates Human Coronary Artery Smooth Muscle Cell Proliferation by Inhibiting Multiple Signaling Pathways That Converge on Cyclin D.

Authors:  Raghvendra K Dubey; Jürgen Fingerle; Delbert G Gillespie; Zaichuan Mi; Marinella Rosselli; Bruno Imthurn; Edwin K Jackson
Journal:  Hypertension       Date:  2015-09-28       Impact factor: 10.190

5.  Parallel Post-Translational Modification Scanning Enhancing Hydrogen-Deuterium Exchange-Mass Spectrometry Coverage of Key Structural Regions.

Authors:  Hongda Liu; Dawei Wang; Qiangmin Zhang; Yang Zhao; Tatyana Mamonova; Lei Wang; Cheng Zhang; Sheng Li; Peter A Friedman; Kunhong Xiao
Journal:  Anal Chem       Date:  2019-05-15       Impact factor: 8.008

6.  The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.

Authors:  Hongmei Cui; Qinghui Wang; Duane D Miller; Wei Li
Journal:  Front Pharmacol       Date:  2021-03-25       Impact factor: 5.810

7.  Cotranslational interaction of human EBP50 and ezrin overcomes masked binding site during complex assembly.

Authors:  Krishnendu Khan; Briana Long; Camelia Baleanu-Gogonea; Valentin Gogonea; Gauravi M Deshpande; Kommireddy Vasu; Paul L Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-15       Impact factor: 12.779

8.  A Critical Role for Na+/H+ Exchanger Regulatory Factor 1 in Modulating FcεRI-Mediated Mast Cell Activation.

Authors:  Ananth K Kammala; Meesum Syed; Canchai Yang; Christopher J Occhiuto; Hariharan Subramanian
Journal:  J Immunol       Date:  2020-12-23       Impact factor: 5.422

9.  β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy.

Authors:  Concetta Saponaro; Sara Sergio; Antonio Coluccia; Maria De Luca; Giuseppe La Regina; Luca Mologni; Valeria Famiglini; Valentina Naccarato; Daniela Bonetti; Candice Gautier; Stefano Gianni; Daniele Vergara; Michel Salzet; Isabelle Fournier; Cecilia Bucci; Romano Silvestri; Carlo Gambacorti Passerini; Michele Maffia; Addolorata Maria Luce Coluccia
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.